A continuing need for biostatistical collaboration throughout the institution and in all stages of clinical and translational research, including planning, design, conduct and data management, intermit and final analysis and reporting. The Biostatistical Resource Group (BRG) provides this consultation and collaboration for clinical investigators and basic scientists who hold National Cancer Institute funded grants or support from other approved peer-reviewed funding agencies. The staff from the BRG, in conjunction with the Clinical Trials Support Resource, participate in the review of a large number of clinical protocols that are developed at the M.D. Anderson Cancer Center or through cooperative groups and pharmaceutical corporation collaboration. From January 1, 1996 through December 31, 1996, 225 protocols were reviewed including 36 Phase I, 71 Phase II, 25 Phase III, 1 Phase IV, 12 Pilot, and 80 other studies. This number is expected to increase by 10 to 15% yearly. The Biostatistical Resource Group provides training in the area of biostatistical principles and methods for the design and analysis of studies. In conjunction with staff from the Division of Medicine, statistical and design issue pertinent to Phase I-III clinical trials have been incorporated into the training program. The BRG also develops a modest amount of biostatistical software for the design, monitoring and analysis of trials in which they are involved. The Biostatistics Resource Group is housed within the Department of Biomathematics in the Houston Main Building. In this environment, they are supported by the latest workstations, servers, and laser printers and the modern statistical and database management software packages.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016672-24
Application #
6101820
Study Section
Project Start
1999-07-01
Project End
2000-06-30
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
24
Fiscal Year
1999
Total Cost
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
001910777
City
Houston
State
TX
Country
United States
Zip Code
77030
Assi, Rita; Garcia-Manero, Guillermo; Ravandi, Farhad et al. (2018) Addition of eltrombopag to immunosuppressive therapy in patients with newly diagnosed aplastic anemia. Cancer 124:4192-4201
Alhuraiji, Ahmad; Kantarjian, Hagop; Boddu, Prajwal et al. (2018) Prognostic significance of additional chromosomal abnormalities at the time of diagnosis in patients with chronic myeloid leukemia treated with frontline tyrosine kinase inhibitors. Am J Hematol 93:84-90
Luo, Yangkun; Xu, Yujin; Liao, Zhongxing et al. (2018) Automatic segmentation of cardiac substructures from noncontrast CT images: accurate enough for dosimetric analysis? Acta Oncol :1-7
Zhao, Na; Cao, Jin; Xu, Longyong et al. (2018) Pharmacological targeting of MYC-regulated IRE1/XBP1 pathway suppresses MYC-driven breast cancer. J Clin Invest 128:1283-1299
Liu, Yihua; Weber, Zachary; San Lucas, F Anthony et al. (2018) Assessing inter-component heterogeneity of biphasic uterine carcinosarcomas. Gynecol Oncol 151:243-249
Joint Head and Neck Radiotherapy-MRI Development Cooperative (2018) Dynamic contrast-enhanced magnetic resonance imaging for head and neck cancers. Sci Data 5:180008
Jensen, Garrett; Tao, Randa; Eng, Cathy et al. (2018) Treatment of primary rectal adenocarcinoma after prior pelvic radiation: The role of hyperfractionated accelerated reirradiation. Adv Radiat Oncol 3:595-600
Staffas, Anna; Burgos da Silva, Marina; Slingerland, Ann E et al. (2018) Nutritional Support from the Intestinal Microbiota Improves Hematopoietic Reconstitution after Bone Marrow Transplantation in Mice. Cell Host Microbe 23:447-457.e4
Boddu, Prajwal; Borthakur, Gautam; Koneru, Mythili et al. (2018) Initial Report of a Phase I Study of LY2510924, Idarubicin, and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia. Front Oncol 8:369
Takahashi, Nobuaki; Chen, Hsing-Yu; Harris, Isaac S et al. (2018) Cancer Cells Co-opt the Neuronal Redox-Sensing Channel TRPA1 to Promote Oxidative-Stress Tolerance. Cancer Cell 33:985-1003.e7

Showing the most recent 10 out of 12418 publications